<p>Severe Hypertriglyceridemia (SHTG) is characterized by extremely high levels of triglycerides in the blood, which increases the risk for cardiovascular diseases and pancreatitis. Early diagnosis and effective treatment are crucial to managing this condition.</p>
<h2><strong>SHTG Epidemiological Segmentation</strong></h2>
<p>The Epidemiological Segmentation of Severe Hypertriglyceridemia (SHTG) in the 7MM includes:</p>
<ul>
<li>Total Diagnosed Prevalent Cases of SHTG</li>
<li>Type-specific Diagnosed Prevalent Cases of SHTG</li>
<li>Treatable Cases of SHTG</li>
</ul>
<h2><a href="https://www.delveinsight.com/report-store/severe-hypertriglyceridemia-shtg-epidemiology-forecast"><span style="text-decoration: underline;"><strong>SHTG Epidemiology</strong></span></a></h2>
<ul>
<li>In 2023, the total diagnosed prevalent cases of SHTG in the 7MM were around 3.6 million.</li>
<li>The US accounted for the highest number of diagnosed prevalent cases of SHTG in 2023, with approximately 2.7 million cases.</li>
<li>Among the EU4 and the UK, Germany had the highest number of cases of SHTG, while Spain accounted for the lowest number of cases in 2023.</li>
<li>A significant portion of SHTG patients remain undiagnosed, and of those diagnosed, approximately 50% do not receive treatment. This indicates a gap in both diagnosis and management.</li>
</ul>
<h2><a href="https://www.delveinsight.com/report-store/severe-hypertriglyceridemia-shtg-market"><span style="text-decoration: underline;"><strong>SHTG Market</strong></span></a></h2>
<p>The total market size of Severe Hypertriglyceridemia (SHTG) in the 7MM was around USD 1.4 billion in 2023.</p>
<h2>SHTG Market Drivers</h2>
<ul>
<li>Increasing awareness of the cardiovascular risks associated with high triglyceride levels is driving market growth.</li>
<li>The development of targeted therapies for managing severe hypertriglyceridemia is expected to positively impact the market.</li>
</ul>
<h2>SHTG Market Barriers</h2>
<ul>
<li>Significant underdiagnosis and undertreatment of SHTG patients present major challenges in managing the disease.</li>
<li>Limited availability of approved treatments further limits patient management options.</li>
</ul>
<h2><a href="https://www.delveinsight.com/report-store/severe-hypertriglyceridemia-shtg-pipeline-insight"><span style="text-decoration: underline;"><strong>SHTG Emerging Therapies</strong></span></a></h2>
<ul>
<li>Olezarsen</li>
<li>Plozasiran (ARO-APOC3)</li>
<li>Pegozafermin (BIO89-100)</li>
<li>SEFA-1024 (NST-1024)</li>
</ul>
<p>And others</p>
<h2><strong>SHTG Key Players</strong></h2>
<ul>
<li>Amarin Corporation</li>
<li>Ionis Pharmaceuticals</li>
<li>Arrowhead Pharmaceuticals</li>
<li>89bio</li>
<li>NorthSea Therapeutics B.V.</li>
<li>MediciNova</li>
</ul>
<p>And others</p>

Severe Hypertriglyceridemia Market

Severe Hypertriglyceridemia Market Infographics

Severe Hypertriglyceridemia Symptoms, Treatment, epidemiology, companies, drugs, infographic is a short guide to understand the problem and market landscape